Form 8-K - Current report:
SEC Accession No. 0001437749-25-001557
Filing Date
2025-01-22
Accepted
2025-01-22 16:02:43
Documents
14
Period of Report
2025-01-20
Items
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 5.01: Changes in Control of Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20250122_8k.htm   iXBRL 8-K 25533
  Complete submission text file 0001437749-25-001557.txt   146115

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pbla-20250120.xsd EX-101.SCH 3409
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20250120_def.xml EX-101.DEF 10353
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20250120_lab.xml EX-101.LAB 13836
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20250120_pre.xml EX-101.PRE 10348
16 EXTRACTED XBRL INSTANCE DOCUMENT pbla20250122_8k_htm.xml XML 2552
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 25545913
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)